Novak, Doroteja, farmacevtka, 1993-
Doroteja Novak
VIAF ID: 84154440089635341052 ( Personal )
Permalink: http://viaf.org/viaf/84154440089635341052
Preferred Forms
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Breaking the paradigm radiolabelled CCK2r antagonists are superior to radiolabelled agonists in in vivo setting | |
CCK2R antagonists : from SAR to clinical trials | |
Conventional radiopharmacy organization and instrumentation | |
Cyclohexyl amide-based novel bacterial topoisomerase inhibitors with prospective GyrA-binding fragments | |
Development of the 99mTc-labelled SST2 antagonist TECANT-1 for a first-in-man multicentre clinical study | |
Exploring alternative pathways to target bacterial type II topoisomerases using NBTI antibacterials: beyond halogen-bonding interactions | |
Načrtovanje in sinteza novih zaviralcv podenote A bakterijske DNA giraze = Design and synthesis of novel bacterial DNA gyrase A inhibitors : enoviti magistrski študijski program Farmacija | |
Novel radiolabelled cholecystokinin-2/gastrin receptor antagonists | |
The quest for the first potent in vivo acting OGT inhibitor | |
Rational design, synthesis and radiolabelling of novel potential CCK2R antagonists | |
Selection of the first [sup]99mTc-labelled somatostatin receptor subtype 2 antagonist for clinical translation-preclinical assessment of two optimized candidates |